When a Skin Lesion Looks Clear: Can RCM Help Detect Residual Disease?

A 2026 systematic review of 56 studies examines how reflectance confocal microscopy can support treatment-response monitoring after PDT, cryotherapy, laser, and topical therapies.

The treated area looks better. Crusting has resolved, the lesion has flattened, and the remaining erythema may appear consistent with normal healing.

Yet clinical improvement can leave one question unresolved: have the abnormal microscopic structures disappeared as well?

That question is particularly relevant after nonsurgical or minimally invasive treatment of actinic keratosis, basal cell carcinoma, and other nonmelanocytic lesions. Photodynamic therapy, cryotherapy, topical drugs, and ablative procedures all alter the surface appearance of the skin. Healing, inflammation, and tissue remodeling can make treatment response difficult to judge from clinical appearance alone.

A 2026 systematic review examined the use of reflectance confocal microscopy for RCM treatment monitoring after these therapies. It included 56 publications: 40 on squamous lesions such as actinic keratosis and squamous cell carcinoma, 15 on basal cell carcinoma, and one on extramammary Paget disease. Treatments included PDT, cryosurgery, ablative laser, 5-fluorouracil, imiquimod, tirbanibulin, and other local or combined approaches. [1] PubMed

The evidence supports a focused role for RCM: it can show whether superficial cellular and architectural abnormalities have improved, persisted, or disappeared after treatment. It does not provide a standalone confirmation of cure.

What the 2026 Systematic Review Found

The review focused on treatment response rather than initial diagnosis.

Across the included studies, RCM was used before and after therapy to compare microscopic features over time. The evidence base was heterogeneous, ranging from randomized and observational studies to case series and individual reports. Because lesions, treatments, follow-up schedules, and imaging criteria varied, the review does not provide one sensitivity, specificity, clearance rate, or recurrence rate that applies across all settings. [1] PubMed

What it does provide is a consistent picture of how RCM has been used to assess response.

In squamous lesions, favorable treatment response was associated with normalization of the epidermal honeycomb pattern and reductions in features such as scaling, parakeratosis, and keratinocyte atypia.

In basal cell carcinoma, disappearance of characteristic tumor islands was one of the main RCM features reported in lesions considered to have achieved complete treatment response. [1]

The review also found that microscopic abnormalities could occasionally remain visible when the treated area appeared clinically clear. This gap between surface appearance and microscopic architecture is the main reason post-treatment RCM has attracted clinical interest.

Why Clinical Healing May Not Equal Microscopic Clearance

Follow-up after nonsurgical therapy differs from follow-up after excisional surgery.

Surgical excision produces tissue that can be examined histologically. PDT, topical therapy, cryotherapy, and ablative treatment usually do not provide a comparable post-treatment specimen.

Assessment therefore relies on the appearance of the treated site, dermoscopy, the subsequent clinical course, and additional investigation when uncertainty remains.

The treatment reaction itself can complicate this assessment. Erythema, edema, scale, crusting, fibrosis, and remodeling may all persist during healing. Conversely, a lesion may become flatter and much less visible while microscopic abnormalities remain.

The 2026 review reported cases in which clinical or dermoscopic examination suggested complete response while RCM continued to show features associated with residual actinic keratosis or basal cell carcinoma. [1]

RCM adds a different layer of information because it allows repeated inspection of superficial cellular architecture without taking another tissue sample.

That information becomes most useful when the visible result and the level of clinical certainty do not match.

What RCM Looks for After Treatment

The relevant confocal findings depend on the lesion being followed.

Actinic Keratosis and Other Squamous Lesions

For actinic keratosis, RCM commonly evaluates the organization of the epidermis and the persistence of keratinocyte atypia.

Features of active disease can include an atypical honeycomb pattern, disordered epidermal architecture, parakeratosis, and abnormal keratinocytes.

As treatment response develops, the epidermal pattern may become more regular and atypical features may diminish.

A 2025 systematic review focused specifically on RCM actinic keratosis monitoring and highlighted keratinocyte atypia and architectural disarray as important response features. It also noted that no universally accepted post-treatment RCM scoring system has yet been established. [2] PubMed

A more regular honeycomb pattern can support a favorable treatment response, but it should not be interpreted as proof of complete histologic clearance.

Basal Cell Carcinoma

BCC has a different confocal pattern.

Typical findings may include basaloid tumor islands, peripheral palisading, peritumoral clefting, and associated vascular or inflammatory changes.

After treatment, disappearance of tumor islands is an important finding in the literature reviewed in 2026. Persistent tumor islands, on the other hand, raise concern that the surface response may not represent complete microscopic clearance. [1]

Post-treatment BCC can still be difficult to interpret.

A 2026 prospective study of superficial BCC found that fibrosis, scar formation, vascular changes, and other structural alterations may remain after therapy and complicate confocal assessment. [3] PubMed

For RCM basal cell carcinoma follow-up, the task is therefore not simply to distinguish tumor from normal skin. The interpreter also has to account for the structural consequences of treatment itself.

Timing Post-Treatment RCM

Early treatment reactions can limit the value of immediate imaging.

PDT, cryotherapy, 5-FU, imiquimod, and ablative procedures can produce pronounced inflammation, edema, crusting, or erosion. RCM can visualize inflammatory changes, but a heavily inflamed field may obscure the features relevant to treatment response.

The 2026 systematic review therefore suggests waiting before formal assessment.

For squamous lesions, the authors recommend beginning RCM evaluation at least one month after treatment.

For BCC, they recommend formal post-treatment RCM assessment from at least three months after therapy. [1]

These are practical recommendations derived from the studies included in the review. They are not universal schedules for every lesion or every treatment.

Timing should still reflect the disease, the therapy used, the clinical course, and the reason for imaging. Earlier RCM may occasionally be used when incomplete response is suspected, whereas formal response assessment may be more interpretable once acute treatment-related inflammation has subsided.

A BCC Case Where RCM Changed the Next Step

A published case illustrates how post-treatment RCM can influence management without being treated as a test of cure.

A 41-year-old woman had recurrent nodular BCC on the nasal dorsum after previous PDT. Because of the cosmetically sensitive location and her preference for a nonsurgical approach, she underwent CO₂ laser treatment followed by two PDT sessions. [4] PubMed

At six weeks, RCM showed fewer basaloid tumor islands than before treatment, but the islands had not disappeared completely.

Two additional PDT sessions were subsequently performed.

At 3, 12, and 30 months, the treated site still showed mild hypopigmentation clinically and erythema on dermoscopy, while RCM no longer demonstrated BCC criteria. [4]

This report involved a single patient and does not establish that RCM improves survival or reduces long-term recurrence.

Its clinical value lies in the sequence of events: the lesion had responded, but the confocal examination still showed residual tumor structure. That information contributed to the decision to continue treatment rather than assuming the initial response was complete.

How RCM Findings Can Change Follow-Up

Post-treatment RCM does not produce a single automatic next step.

Persistent suspicious features may support closer observation, repeat imaging, targeted biopsy, additional treatment, or referral for surgery. The choice depends on the lesion, anatomical site, previous treatment, patient risk, and the confidence of the imaging interpretation.

A reassuring RCM examination can support continued follow-up, but it does not exclude disease outside the scanned area or below the accessible imaging depth.

This is an important limitation of RCM residual disease assessment.

The scan covers a finite field, and reflectance confocal microscopy is primarily suited to the epidermis and superficial dermis. Small residual foci outside the imaged area or deeper components may not be visualized.

RCM is most useful when it adds enough information to refine the next clinical decision.

Where RCM Helps—and Where Histopathology Still Matters

RCM offers a clear practical advantage: the same skin site can be examined repeatedly without removing tissue.

It also has limitations that remain relevant after treatment.

Imaging depth is restricted. The examined field is finite. Image quality and interpretation depend on acquisition technique and operator experience. Post-treatment inflammation and fibrosis can obscure or mimic disease-related features.

When tissue confirmation is required, histopathology remains necessary.

A suspicious confocal finding may help identify where a biopsy should be taken rather than eliminating the need for biopsy. This is particularly important when the clinical examination, dermoscopy, and RCM do not agree or when treatment decisions depend on definitive tumor characterization.

For a broader discussion of this diagnostic pathway, see our review of RCM and skin biopsy decision-making:

https://www.kernelmedint.com/news/reflectance-confocal-microscopy-skin-biopsy

Post-treatment RCM therefore complements clinical examination and histopathology rather than replacing either one. Your existing biopsy-focused article makes the same boundary clear in the broader diagnostic workflow. Kernel Medical Equipment

When Post-Treatment RCM May Add the Most Value

RCM is unlikely to be necessary after every treated lesion.

Its strongest role is in situations where superficial microscopic information could reasonably change follow-up.

Cosmetically sensitive facial sites are one example. Repeated biopsy or additional surgery may have greater consequences in these areas, so a noninvasive examination can be useful when clinical uncertainty persists.

Another useful setting is discordance between clinical appearance and dermoscopy. A lesion may appear flat while dermoscopic findings remain equivocal, or the surface may still look inflamed even though microscopic architecture is returning toward normal.

RCM may also be helpful when residual or recurrent disease is suspected after nonsurgical treatment and repeated assessment of the same site is desirable.

These are treatment-response questions. They are different from the diagnostic workflow addressed in earlier KernelMed content on equivocal lesions and biopsy decisions.

For the wider diagnostic pathway, see RCM in skin cancer workflows:

https://www.kernelmedint.com/news/reflectance-confocal-microscopy-skin-cancer-workflow

That earlier article focuses on the role of RCM after dermoscopy and before or around biopsy decisions, which keeps the search intent clearly separate from this post-treatment monitoring article. Kernel Medical Equipment

Where the RCM System Fits

Once post-treatment confocal imaging has a justified role in the clinical workflow, equipment capabilities become relevant.

KernelMed's RCM-9503 Reflectance Confocal Microscopy System is designed for in vivo cellular-level imaging of the epidermis and superficial dermis. The current product page lists an 830 nm laser, imaging depth of at least 300 μm, a 500 × 500 μm scanning field, and image stitching up to 8.5 × 8.5 mm. Kernel Medical Equipment

For follow-up work, the most relevant capabilities are cellular-level imaging, image stitching, lesion documentation, and repeat comparison across visits.

Product page:

https://www.kernelmedint.com/product/rcm-precision-skin-imaging-non-invasive-real-time-diagnosis

These capabilities support longitudinal imaging, but they should be kept separate from the clinical outcomes reported in the literature.

The findings in the 2026 systematic review relate to RCM as an imaging modality, not to device-specific outcomes for the KernelMed RCM-9503.

The usefulness of treatment monitoring still depends on lesion selection, image acquisition, interpretation, treatment history, and appropriate use of histopathology when tissue confirmation is needed.

Conclusion

Post-treatment assessment is often straightforward when a lesion resolves and follow-up remains reassuring. RCM becomes more relevant when clinical healing leaves uncertainty about superficial residual disease.

In that setting, reflectance confocal microscopy can add microscopic information that helps determine whether continued observation is reasonable or whether repeat imaging, biopsy, or additional treatment should be considered.

RCM is best used as an adjunct to clinical assessment, dermoscopy, and histopathology when post-treatment findings remain uncertain.

FAQ

Can RCM detect residual disease after skin cancer treatment?

RCM can identify superficial microscopic features that remain suspicious after treatment, including persistent BCC tumor islands or abnormal keratinocyte architecture. Findings should be interpreted together with clinical examination, dermoscopy, treatment history, and histopathology when tissue confirmation is required. [1]

What can RCM show after actinic keratosis treatment?

RCM may show a more regular epidermal honeycomb pattern and reductions in parakeratosis, keratinocyte atypia, and architectural disarray. No universally accepted post-treatment RCM scoring system for AK has yet been established. [1,2]

What does RCM monitor after basal cell carcinoma treatment?

RCM can assess whether characteristic BCC features such as basaloid tumor islands remain visible. Disappearance of tumor islands is associated with complete treatment response in the reviewed literature, although fibrosis and other treatment-related changes can complicate interpretation. [1,3]

When should RCM be performed after treatment?

The 2026 systematic review suggests beginning formal RCM assessment at least one month after treatment for squamous lesions and at least three months after treatment for BCC. These are review-derived recommendations rather than mandatory schedules for every patient. [1]

Can RCM replace a biopsy after treatment?

No. RCM can help refine follow-up and identify areas that warrant targeted biopsy, but histopathology remains necessary when definitive tissue confirmation is clinically required.

References

[1] Villa-Gonzalez JM, Gonzalez-Hermosa MR, Ardigò M, Gonzalez S.
Monitoring the Effectiveness of Noninvasive or Minimally Invasive Therapies for Nonmelanocytic Lesions Using Reflectance Confocal Microscopy: A Systematic Review.
Actas Dermo-Sifiliográficas. 2026;117(1):104492.
doi:10.1016/j.ad.2025.104492. PubMed

[2] Zhang J, Ran H, Zhao Y, et al.
The Clinical Value of Reflectance Confocal Microscopy in Monitoring Treatment of Actinic Keratosis: A Systematic Review.
Photodiagnosis and Photodynamic Therapy. 2025;53:104539. PubMed

[3] Clark M, Wuennenberg J, Maghfour J, et al.
Reflectance confocal microscopy for monitoring treatment response in superficial basal cell carcinoma: diagnostic challenges due to scar formation.
Clinical and Experimental Dermatology. 2026;51(2):244–249.
doi:10.1093/ced/llaf407. PubMed

[4] Alma A, Pongetti L, Clementi A, et al.
Combined Carbon Dioxide Laser with Photodynamic Therapy for Nodular Basal Cell Carcinoma Monitored by Reflectance Confocal Microscopy.
Medicina (Kaunas). 2024;60(1):30.
doi:10.3390/medicina60010030. PubMed